Image 5_Fatty acid synthase inhibition improves hypertension-induced erectile dysfunction by suppressing oxidative stress and NLRP3 inflammasome-dependent pyroptosis through activa... حسب Jiaochen Luan (9704384)

"…In vitro, siFasn and C75 enhanced antioxidant markers Nrf2 and HO-1, reduced ROS accumulation, and suppressed NLRP3 and GSDMD levels. In vivo, C75 treatment restored endothelial function and reversed erectile dysfunction, accompanied by decreased oxidative stress and pyroptosis in the penile corpus cavernosum.…"

Data Sheet 1_Fatty acid synthase inhibition improves hypertension-induced erectile dysfunction by suppressing oxidative stress and NLRP3 inflammasome-dependent pyroptosis through a... حسب Jiaochen Luan (9704384)

"…In vitro, siFasn and C75 enhanced antioxidant markers Nrf2 and HO-1, reduced ROS accumulation, and suppressed NLRP3 and GSDMD levels. In vivo, C75 treatment restored endothelial function and reversed erectile dysfunction, accompanied by decreased oxidative stress and pyroptosis in the penile corpus cavernosum.…"

Table 1_Unveiling the global impact of hypertensive heart disease among individuals aged ≥ 65 years: metabolic risk factors and future projections for 2050.xlsx حسب Ning An (618997)

"…Join-point analysis revealed an increasing trend in age-standardized prevalence rates between 1990 and 2021, while mortality and DALYs rates decreased. …"

Table 4_Unveiling the global impact of hypertensive heart disease among individuals aged ≥ 65 years: metabolic risk factors and future projections for 2050.xlsx حسب Ning An (618997)

"…Join-point analysis revealed an increasing trend in age-standardized prevalence rates between 1990 and 2021, while mortality and DALYs rates decreased. …"

Image 1_Unveiling the global impact of hypertensive heart disease among individuals aged ≥ 65 years: metabolic risk factors and future projections for 2050.tif حسب Ning An (618997)

"…Join-point analysis revealed an increasing trend in age-standardized prevalence rates between 1990 and 2021, while mortality and DALYs rates decreased. …"

Table 3_Unveiling the global impact of hypertensive heart disease among individuals aged ≥ 65 years: metabolic risk factors and future projections for 2050.xlsx حسب Ning An (618997)

"…Join-point analysis revealed an increasing trend in age-standardized prevalence rates between 1990 and 2021, while mortality and DALYs rates decreased. …"

Table 2_Unveiling the global impact of hypertensive heart disease among individuals aged ≥ 65 years: metabolic risk factors and future projections for 2050.xlsx حسب Ning An (618997)

"…Join-point analysis revealed an increasing trend in age-standardized prevalence rates between 1990 and 2021, while mortality and DALYs rates decreased. …"

Image 1_Population pharmacokinetics of polymyxin B in critically ill patients with carbapenem-resistant organisms infections: insights from steady-state trough and peak plasma conc... حسب Jun Yang (2084)

"…PTA decreased as CrCL increased, with slight variations observed across different PLT levels. …"

Epidural Hydromorphone for Postpartum Pain Management After Vaginal Delivery: A Randomized Clinical Trial حسب Yixing Lu (19234084)

"…Postpartum inflammatory markers, including leukocyte count (13.53 ± 3.26 vs. 13.91 ± 3.20) and ultrasensitive C-reactive protein levels (62.69 ± 38.00 vs. 65.93 ± 36.20), were lower in the HY group, although these differences did not reach statistical significance.…"

<i>Tg</i>ATM1-depleted <i>Toxoplasma</i> are functionally complemented through expression of the <i>Plasmodium</i> or yeast homolog. حسب Deepti Shrivastava (17715780)

"…The number of significantly increased and decreased proteins is given and the NEET proteins CDGSH1 and CDGSH2 as well as <i>Tg</i>ATM1 are indicated.…"

Table 2_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx حسب Chao-Chao Chen (21090215)

"…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …"

Image 3_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff حسب Chao-Chao Chen (21090215)

"…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …"

Table 1_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx حسب Chao-Chao Chen (21090215)

"…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …"

Image 2_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff حسب Chao-Chao Chen (21090215)

"…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …"

Table 3_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx حسب Chao-Chao Chen (21090215)

"…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …"

Image 1_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff حسب Chao-Chao Chen (21090215)

"…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …"

Image 8_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tif حسب Chao-Chao Chen (21090215)

"…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …"

Image 6_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff حسب Chao-Chao Chen (21090215)

"…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …"

Image 4_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tif حسب Chao-Chao Chen (21090215)

"…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …"

Image 7_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff حسب Chao-Chao Chen (21090215)

"…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …"